Clinical Trial Update: Cladribine in Combination With CAG in Patients With Refractory/Relapsed Acute Myeloid Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a cladribine-based combination (CAG) in patients with refractory/relapsed acute myeloid leukemia; status is currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Leukemia

Drugs mentioned

• CAG
• Cladribine (cladribine)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Acute Myeloid Leukemia, Relapse Leukemia | Phase 2 | Status: UNKNOWN